Manning LS - Search Results

1

Establishment of a murine model of malignant mesothelioma.

Davis MR, Manning LS, Whitaker D, Garlepp MJ, Robinson BW. Davis MR, et al. Among authors: manning ls. Int J Cancer. 1992 Dec 2;52(6):881-6. doi: 10.1002/ijc.2910520609. Int J Cancer. 1992. PMID: 1459729

2

In vitro stage-specific sensitivity of Plasmodium falciparum to quinine and artemisinin drugs.

Skinner TS, Manning LS, Johnston WA, Davis TM. Skinner TS, et al. Among authors: manning ls. Int J Parasitol. 1996 May;26(5):519-25. doi: 10.1016/0020-7519(96)89380-5. Int J Parasitol. 1996. PMID: 8818732

3

Radiopharmaceutical therapy of 5T33 murine myeloma by sequential treatment with samarium-153 ethylenediaminetetramethylene phosphonate, melphalan, and bone marrow transplantation.

Turner JH, Claringbold PG, Manning LS, O'Donoghue HL, Berger JD, Glancy RJ. Turner JH, et al. Among authors: manning ls. J Natl Cancer Inst. 1993 Sep 15;85(18):1508-13. doi: 10.1093/jnci/85.18.1508. J Natl Cancer Inst. 1993. PMID: 8360933

4

Effect of interferon-alpha 2a on malignant mesothelioma.

Christmas TI, Manning LS, Garlepp MJ, Musk AW, Robinson BW. Christmas TI, et al. Among authors: manning ls. J Interferon Res. 1993 Feb;13(1):9-12. doi: 10.1089/jir.1993.13.9. J Interferon Res. 1993. PMID: 8454913

5

An analysis of the relationship between gamma delta T cell receptor V gene usage and non-major histocompatibility complex-restricted cytotoxicity.

Mavaddat N, Robinson BW, Rose AH, Manning LS, Garlepp MJ. Mavaddat N, et al. Among authors: manning ls. Immunol Cell Biol. 1993 Feb;71 ( Pt 1):27-37. doi: 10.1038/icb.1993.3. Immunol Cell Biol. 1993. PMID: 8436409

6

Patho- and immunobiology of malignant mesothelioma: characterisation of tumour infiltrating leucocytes and cytokine production in a murine model.

Bielefeldt-Ohmann H, Fitzpatrick DR, Marzo AL, Jarnicki AG, Himbeck RP, Davis MR, Manning LS, Robinson BW. Bielefeldt-Ohmann H, et al. Among authors: manning ls. Cancer Immunol Immunother. 1994 Dec;39(6):347-59. doi: 10.1007/BF01534421. Cancer Immunol Immunother. 1994. PMID: 8001022

7

Indomethacin augments lymphokine-activated killer cell generation by patients with malignant mesothelioma.

Manning LS, Bowman RV, Davis MR, Musk AW, Robinson BW. Manning LS, et al. Clin Immunol Immunopathol. 1989 Oct;53(1):68-77. doi: 10.1016/0090-1229(89)90102-5. Clin Immunol Immunopathol. 1989. PMID: 2788546

8

Lysis of human malignant mesothelioma cells by natural killer (NK) and lymphokine-activated killer (LAK) cells.

Manning LS, Bowman RV, Darby SB, Robinson BW. Manning LS, et al. Am Rev Respir Dis. 1989 Jun;139(6):1369-74. doi: 10.1164/ajrccm/139.6.1369. Am Rev Respir Dis. 1989. PMID: 2786360

9

In vivo boosting of lung natural killer and lymphokine-activated killer cell activity by interleukin-2: comparison of systemic, intrapleural and inhalation routes.

Flexman JP, Manning LS, Robinson BW. Flexman JP, et al. Among authors: manning ls. Clin Exp Immunol. 1990 Oct;82(1):151-6. doi: 10.1111/j.1365-2249.1990.tb05419.x. Clin Exp Immunol. 1990. PMID: 2208789 Free PMC article.

10

Interaction between dactinomycin and tumor necrosis factor in mesothelioma. Cachexia without oncolysis.

Bowman RV, Whitaker D, Manning LS, Davis MR, Robinson BW. Bowman RV, et al. Among authors: manning ls. Cancer. 1991 May 15;67(10):2495-500. doi: 10.1002/1097-0142(19910515)67:10<2495::aid-cncr2820671018>3.0.co;2-8. Cancer. 1991. PMID: 2015549

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results